Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Data from 2021 and 2022 showed that biosimilar use within an Italian health care company was on the rise, suggesting that the country could achieve total utilization in the coming years. The researchers touted the growing success, saying that more use will benefit the National Health System (NHS) and citizens who rely on an efficient and sustainable health care policy.
High production costs associated with biologics have posed concerns about the sustainability of health care systems globally, with biosimilars being presented as cost-effective alternatives priced at about 20% to 30% less than reference agents. Increased utilization of biosimilars could reduce biologic prices even more. Tender systems, which Italy uses, allow for greater biosimilar utilization and price reductions by allowing biosimilars and reference products to compete on pricing in hopes of being granted a contract with the region’s public health plan.
“The advent of biosimilar drugs represents a transformative milestone in the landscape of therapeutic biologics, offering a promising avenue for better access to care for patients and potential economic benefits for health care systems worldwide,” the authors wrote.
The present study compared dosing unit quantity and financial expenditure between originator and biosimilar products in an Italian health care facility serving around 1.1 million people, aiming to identify cost-saving opportunities. The researchers said they hope their results will inform pharmaceutical selection and resource allocation in the local health care system.
The Local Health Authority Napoli 3 South includes 5 hospitals and 10 health districts, with one of the highest population densities in Italy of 1737 inhabitants per square kilometer. The assessment included prescriptions distributed through private pharmacies working with the NHS and those dispensed at corporate health care facilities.
The authors utilized the Anatomical, Therapeutic and Chemical (ATC) classification system to select drugs of interest. Consumption, expenditure, and patient numbers were extracted from the company's databases. A comparison was then made with 2021 to assess the increase in biosimilar drug usage in 2022.
In 2022, the analysis showed that while most drug classes within the company's territory still preferred originator drugs, some showed a shift toward biosimilar usage. Notably, insulins largely favored originators, with only minor usage of biosimilars observed (insulin lispro, 100.0% vs 0.0%; insulin aspart, 99.3% vs 0.7%; insulin glargine, 83.4% vs. 16.6%). However, drugs like enoxaparin and erythropoietin had mostly transitioned to biosimilars (enoxaparin, 99.2%; erythropoietin, 98.8%). High biosimilar utilization was seen in trastuzumab (98.4%), filgrastim (99.8%), and pegfilgrastim (98.4%), with 100% utilization regarding rituximab and bevacizumab. Drugs like etanercept and adalimumab had room for increased biosimilar usage (73.3% and 73.8%, respectively). Infliximab, particularly for chronic diseases, showed a preference for biosimilars at 96.0%. These data indicate a widespread trend toward biosimilar usage compared with originators (86.8% vs 13.2%).
The analysis revealed an overall balance in expenditure between originator and biosimilar drugs, with significant opportunities for cost recovery identified in specific drug classes like insulin glargine, somatropin, etanercept, and adalimumab. Although biosimilar drugs were prioritized over originators, spending did not reflect this trend, with comparable expenditure on both types (53.1% for biosimilars and 46.9% for originators) out of a total expenditure of €11,026,545.62 ($11,975,379.87).
The number of patients treated with biosimilar drugs was 3 times higher than those treated with originator drugs, except for certain drugs like insulins, etanercept, adalimumab, follitropin, and somatropin. This trend indicates a future trajectory favoring biosimilars, with increasing prospects for cost savings. While some drugs maintained similar usage rates from 2021 to 2022, others showed significant increases in biosimilar usage in 2022, signaling a positive trend towards lower-cost drugs.
The authors concluded that the results are “encouraging, especially for those medicinal specialties that still show a significant consumption of higher-cost drugs. It is crucial to consider that continuous data monitoring, along with ongoing efforts to raise awareness among prescribing clinicians, can lead to an increasing and exclusive use of lower-cost drugs in the coming years. These drugs ensure both the efficacy and safety of treatments and the sustainability of the entire [NHS].”
Reference
Ferrara F, Capuzzo M, Langella R, Trama U, Nava E, Zovi A. The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company. J Cancer Policy. March 18, 2024. doi:10.1016/j.jcpo.2024.100473
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.